COM701 for Ovarian Cancer
(MAIA-ovarian Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an experimental antibody called COM701 to determine if it can slow the progression of ovarian cancer after initial treatments. It examines whether COM701 can delay the need for additional cancer treatments and identifies potential side effects. Suitable candidates have relapsed ovarian, fallopian tube, or primary peritoneal cancer, have undergone at least two rounds of platinum-based treatments, and have experienced some success with their last chemotherapy. Participants will visit the clinic every three weeks for treatment and tests to monitor their health and cancer status. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on immunosuppressive doses of systemic medications like steroids within 2 weeks before starting the study treatment.
Is there any evidence suggesting that COM701 is likely to be safe for humans?
Research has shown that COM701 has been tested in several studies with patients who have platinum-resistant ovarian cancer. In these studies, COM701 was generally well-tolerated, meaning most people did not experience serious problems. Some side effects were reported, but they were manageable. Safety data from past patients indicate that COM701, whether used alone or with other treatments, did not cause severe side effects for most participants. This suggests the treatment is relatively safe. However, like any treatment, side effects can occur and may vary from person to person. Participants should discuss potential risks and benefits with their healthcare provider.12345
Why do researchers think this study treatment might be promising for ovarian cancer?
Researchers are excited about COM701 for ovarian cancer because it represents a novel approach to treatment. Unlike standard therapies like chemotherapy and targeted drugs, which often focus on directly killing cancer cells or inhibiting specific growth signals, COM701 is an immunotherapy. It works by targeting a protein called PVRIG, which is involved in suppressing the immune system's response to cancer. By blocking this protein, COM701 aims to unleash the body’s natural defenses to better fight the cancer, potentially offering a new option for patients who don’t respond well to existing treatments.
What evidence suggests that COM701 might be an effective treatment for ovarian cancer?
Research has shown that COM701, which participants in this trial may receive, may help treat ovarian cancer, particularly in patients who have undergone several prior treatments. Studies found that COM701 was generally safe and led to lasting improvements in these patients. In early results, 20% of patients experienced tumor shrinkage, and 25% maintained stable disease, meaning their cancer did not progress. While these findings are promising, more information is needed to fully understand the treatment's effectiveness.23678
Are You a Good Fit for This Trial?
This trial is for individuals with relapsed platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. They must have completed at least two prior platinum-based therapies and recovered from previous treatment side effects (except mild neuropathy and hair loss). Participants should have responded to their last chemotherapy and may not be candidates for or have declined certain other maintenance therapies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive COM701 or placebo intravenously every 3 weeks as maintenance therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- COM701
Find a Clinic Near You
Who Is Running the Clinical Trial?
Compugen Ltd
Lead Sponsor